A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Trastuzumab treatment in patients with breast cancer is associated with differential expression of the Wilms' tumor susceptibility gene, WT1
[post]
2020
unpublished
Preserved Fulltext
The mechanism of action underlying trastuzumab (Herceptin) function is ascribed to binding of the Fab region of trastuzumab to the extracellular domain of the human epidermal growth factor receptor (HER2) (1). The transcriptional responses that follow signals transduced through trastuzumab binding to HER2 are less well understood. We mined published microarray and multiplexed gene expression data (2, 3) to understand in an unbiased fashion genes most differentially expressed in the primary
doi:10.31219/osf.io/f2w6y
fatcat:hvadglbp2nalxir7u3le6pcovm